Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. Jul-Aug 2015;21(4):239-44.
doi: 10.4103/1319-3767.161642.

Bactericidal Permeability Increasing Protein Gene Polymorphism Is Associated With Inflammatory Bowel Diseases in the Turkish Population

Affiliations
Free PMC article

Bactericidal Permeability Increasing Protein Gene Polymorphism Is Associated With Inflammatory Bowel Diseases in the Turkish Population

Güray Can et al. Saudi J Gastroenterol. .
Free PMC article

Abstract

Background/aims: Inflammatory bowel disease, a chronic inflammatory disease with unknown etiology, affects the small and large bowel at different levels. It is increasingly considered that innate immune system may have a central position in the pathogenesis of the disease. As a part of the innate immune system, bactericidal permeability increasing protein has an important role in the recognition and neutralization of gram-negative bacteria. The aim of our study was to investigate the involvement of bactericidal permeability increasing protein gene polymorphism (bactericidal permeability increasing protein Lys216Glu) in inflammatory bowel disease in a large group of Turkish patients.

Patients and methods: The present study included 528 inflammatory bowel disease patients, 224 with Crohn's disease and 304 with ulcerative colitis, and 339 healthy controls.

Results: Bactericidal permeability increasing protein Lys216Glu polymorphism was found to be associated with both Crohn's disease and ulcerative colitis (P = 0.0001). The frequency of the Glu/Glu genotype was significantly lower in patients using steroids and in those with steroid dependence (P = 0.012, OR, 0.80; 95% confidence interval [CI]: 0.68-0.94; P = 0.0286, OR, 0.75; 95% CI: 0.66-0.86, respectively). There was no other association between bactericidal permeability increasing protein gene polymorphism and phenotypes of inflammatory bowel disease.

Conclusions: Bactericidal permeability increasing protein Lys216Glu polymorphism is associated with both Crohn's disease and ulcerative colitis. This is the first study reporting the association of bactericidal permeability increasing protein gene polymorphism with steroid use and dependence in Crohn's disease.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
The resulting bands from polymerase chain reaction and restriction fragment length polymorphism procedure for bactericidal permeability increasing protein in study population. m: Marker, k: Control group, -k: Negative control

Similar articles

See all similar articles

Cited by 1 article

References

    1. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15:79–94. - PMC - PubMed
    1. Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J. Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: Pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take “toll”? World J Gastroenterol. 2006;12:1829–41. - PMC - PubMed
    1. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology. 1996;110:1395–403. - PubMed
    1. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut. 1996;38:365–75. - PMC - PubMed
    1. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603–6. - PubMed

Substances

Feedback